SanBio Co 4592.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4592.T. It has been listed since 8 April 2015. In the fiscal year to 31 January 2021, it reported revenue of ¥22.9m and a net loss of ¥3.39bn. At that date it held total assets of ¥13.34bn and shareholders' equity of ¥8.35bn.

SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2015-04-08. The firm has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The firm aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. The company is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The firm has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Toru KawanishiChairman of the Board, Executive Officer, Representative Director, since 2013
• Mr. Keita MoriPresident, Chief Executive Officer, Executive Officer, CEO of Subsidiary, Representative Director, since 2013
• Mr. Naoki TsukaharaManaging Executive Officer
• Mr. Yoshihiro SumiyaExecutive Officer, Director of Business Administration
• Mr. Shinya HirataExecutive Officer, Chief Director of Research and Development
• Mr. Keizo NakataExecutive Officer, Chief Director of Production
• Ms. Kazumi SawaguchiExecutive Officer, Director of Quality Assurance and Regulatory Affairs
• Mr. Noboru KotaniIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.